 |
autologous Epstein-Barr specific T-cells |
|---|---|
| Trade Name | |
| Orphan Indication | Post-transplant lymphoproliferative disorder |
| USA Market Approval | USA |
| USA Designation Date | 2017-05-31 00:00:00 |
| Sponsor | Cell Medica, Inc.;7505 Fannin Street, Suite 200;Houston, Texas, 77054 |
